| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11014632 | Journal of Allergy and Clinical Immunology | 2018 | 17 Pages |
Abstract
Nemolizumab for up to 64Â weeks was efficacious and overall well tolerated in patients with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kenji MD, PhD, Masutaka MD, PhD, Jon M. MD, Grazyna MD, Andreas MD, Ryszard MD, PhD, Takafumi MD, Ryosuke MS, Miwa MS, Thomas MD,